GenMark Diagnostics Rating Reiterated by Piper Jaffray Cos. (GNMK)
GenMark Diagnostics (NASDAQ:GNMK)‘s stock had its “overweight” rating restated by Piper Jaffray Cos. in a research note issued on Monday, Stock Ratings Network.com reports. They currently have a $14.00 price objective on the stock, up from their previous price objective of $9.00. Piper Jaffray Cos.’s target price suggests a potential upside of 11.11% from the stock’s previous close.
A number of other firms have also recently commented on GNMK. Analysts at Raymond James raised their price target on shares of GenMark Diagnostics to $15.00 in a research note to investors on Wednesday, October 2nd. Finally, analysts at Canaccord Genuity cut their price target on shares of GenMark Diagnostics from $18.00 to $14.00 in a research note to investors on Thursday, August 8th. They now have a “buy” rating on the stock. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. GenMark Diagnostics has a consensus rating of “Buy” and an average target price of $14.50.
In other GenMark Diagnostics news, SVP Jon Faiz Kayyem sold 6,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $12.14, for a total value of $72,840.00. The sale was disclosed in a document filed with the SEC, which is available at this link.
Shares of GenMark Diagnostics (NASDAQ:GNMK) traded up 1.78% on Monday, hitting $12.60. 138,142 shares of the company’s stock traded hands. GenMark Diagnostics has a 52 week low of $7.55 and a 52 week high of $16.00. The stock’s 50-day moving average is $11.84 and its 200-day moving average is $12.26. The company’s market cap is $412.5 million.
GenMark Diagnostics (NASDAQ:GNMK) last issued its quarterly earnings data on Wednesday, August 7th. The company reported ($0.25) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.26) by $0.01. The company had revenue of $5.20 million for the quarter, compared to the consensus estimate of $5.05 million. Analysts expect that GenMark Diagnostics will post $-0.87 EPS for the current fiscal year.
GenMark Diagnostics, Inc (NASDAQ:GNMK) is a molecular diagnostics company focused on developing and commercializing its eSensor detection technology.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.